Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them
US-2015361060-A1 · Dec 17, 2015 · US
Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US9630960B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9630960-B2 |
| Application number | US-201615139592-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 27, 2016 |
| Priority date | Apr 7, 2004 |
| Publication date | Apr 25, 2017 |
| Grant date | Apr 25, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides novel quinolinone-carboxamide 5-HT 4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT 4 receptor activity, and processes and intermediates useful for preparing such compounds.
First claim
Opening claim text (preview).
What is claimed is: 1. 1-isopropyl-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid {(1S,3R,5R)-8-[3-formylamino-2-hydroxypropyl]-8-azabicyclo[3.2.1]oct-3-yl}amide of formula or a pharmaceutically-acceptable salt thereof. 2. A pharmaceutical composition comprising 1-isopropyl-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid {(1S,3R,5R)-8-[3-formylamino-2-hydroxypropyl]-8-azabicyclo[3.2.1]oct-3-yl}amide of formula or a pharmaceutically-acceptable salt thereof and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title
Drugs for disorders of the nervous system · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
for treating abnormal movements, e.g. chorea, dyskinesia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9630960B2 cover?
- The invention provides novel quinolinone-carboxamide 5-HT 4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT 4 receptor activity, and processes and intermediates useful for preparing such compounds.
- Who is the assignee on this patent?
- Theravance Biopharma R&D Ip Llc
- What technology area does this patent fall under?
- Primary CPC classification C07D451/02. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).